FY2022 · ended Dec 31, 2022 · Revenue $0, -100.0% YoY · Filed Mar 12, 2024
Corbus Pharmaceuticals Holdings, Inc. (CRBP) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$64.5 million. As of Jun 30, 2026 it held $117.9 million in cash and investments and $4.3 million in total debt.
Revenue
$0
-100.0% vs prior year
Net income
$-78.54M
-95.3% vs prior year
Operating cash flow (TTM)
$-86.67M
-49.7% vs year-ago TTM
Free cash flow
$-64.50M
-78.7% vs prior year
EPS
$-5.90
-60.3% vs prior year
Dividend per share
None
Shares outstanding
17.74M
+45.0% vs prior year
Net cash
$113.68M
as of Jun 30, 2026
Operating margin
-6350.1%
FY 2021
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CRBP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Norwood, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1595097
- Former names
- SAV Acquisition Corp (until Jan 10, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $881,705 |
| Operating income | -$85.3M | -$48.7M | -$45.1M | -$39.8M | -$56.0M |
| Net income | -$78.5M | -$40.2M | -$44.6M | -$42.3M | -$45.6M |
| Diluted EPS | -$5.90 | -$3.68 | -$10.31 | -$10.15 | — |
| Operating cash flow | -$64.5M | -$41.8M | -$36.1M | -$37.5M | -$48.2M |
| Free cash flow | -$64.5M | — | -$36.1M | -$37.6M | -$48.2M |
| Total assets | $168.2M | $155.9M | $28.3M | $66.3M | $107.7M |
| Total liabilities | $20.7M | $13.5M | $35.2M | $33.3M | $38.6M |
| Stockholders' equity | $147.5M | $142.4M | -$6.9M | $33.0M | $69.1M |
| Cash and investments | $163.3M | $149.1M | $20.9M | $59.2M | $97.6M |
| Total debt | $1.6M | $3.2M | $22.6M | $27.5M | $28.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jul 6, 2026 | Jul 2, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 26, 2026 | May 26, 2026 |
All 808 Corbus Pharmaceuticals Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.